PKM and non-small cell lung carcinoma: In cisplatin-resistant non-small cell lung cancer (NSCLC), PKM2 inhibition suppresses aerobic glycolysis and induces a compensatory increase in lipid metabolism through carnitine palmitoyltransferase 1A (CPT1A)-dependent fatty acid oxidation (FAO), sustaining cancer cell survival under chemotherapeutic pressure.